{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+Candidate+%235",
    "query": {
      "intervention": "Vaccine Candidate #5"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 54,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+Candidate+%235&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T00:54:22.644Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02193087",
      "title": "Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "TDV Liquid Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "TDV Liquid Formulation 2",
          "type": "DRUG"
        },
        {
          "name": "TDV IDT Lyophilized",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 1002,
      "start_date": "2014-08-06",
      "completion_date": "2015-05-19",
      "has_results": true,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Anaheim, California • Stockbridge, Georgia + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02193087"
    },
    {
      "nct_id": "NCT00712803",
      "title": "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "rDEN3-3'D4delta30",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 29,
      "start_date": "2008-12",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00712803"
    },
    {
      "nct_id": "NCT01540474",
      "title": "Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Group 1: 10 ug FMP012 with 2 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Group 2: 10 ug FMP012 with 5 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Controlled group-Challenged Only: no vaccination",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-02",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540474"
    },
    {
      "nct_id": "NCT00375726",
      "title": "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "rDEN3/4delta30(ME)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 58,
      "start_date": "2006-10",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2010-12-14",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00375726"
    },
    {
      "nct_id": "NCT02143518",
      "title": "Safety and Immunogenicity Study of Na-GST-1 With or Without CpG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hookworm Infection",
        "Hookworm Disease"
      ],
      "interventions": [
        {
          "name": "Na-GST-1/Alhydrogel®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CpG 10104",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-10",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143518"
    },
    {
      "nct_id": "NCT03718130",
      "title": "Combination HTNV and PUUV DNA Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hantaan Virus Disease, Puumala Virus"
      ],
      "interventions": [
        {
          "name": "Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 61,
      "start_date": "2019-07-10",
      "completion_date": "2022-10-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03718130"
    },
    {
      "nct_id": "NCT02151344",
      "title": "Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Virus, H7N9 Subtype"
      ],
      "interventions": [
        {
          "name": "H7N9 A/Anhui/13 ca influenza virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated subvirion H7N9 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-05",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02151344"
    },
    {
      "nct_id": "NCT03014310",
      "title": "H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Avian Influenza"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "MF59",
          "type": "DRUG"
        },
        {
          "name": "Monovalent Influenza A/H5N8 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 388,
      "start_date": "2017-01-09",
      "completion_date": "2018-12-19",
      "has_results": false,
      "last_update_posted_date": "2024-09-23",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014310"
    },
    {
      "nct_id": "NCT04816643",
      "title": "Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Infection, COVID-19"
      ],
      "interventions": [
        {
          "name": "Biological/Vaccine: BNT162b2 10mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 20mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 30mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Biological/Vaccine: BNT162b2 3mcg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "6 Months to 15 Years"
      },
      "enrollment_count": 11837,
      "start_date": "2021-03-24",
      "completion_date": "2023-12-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 90,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04816643"
    },
    {
      "nct_id": "NCT01728792",
      "title": "Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "TDV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 80,
      "start_date": "2013-01-22",
      "completion_date": "2013-11-21",
      "has_results": true,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-09-17T00:54:22.644Z",
      "location_count": 1,
      "location_summary": "Syracuse, New York",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728792"
    }
  ]
}